Retatrutide 20mg – Research Grade Peptide
Retatrutide Peptide (RUO) | High Purity ≥99% | Research Grade
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Retatrutide (LY3437943) |
| Peptide Type | Synthetic Triple-Hormone Receptor Agonist — 39 Amino Acids |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | ~4,731 Da |
| Target Receptors | GIP / GLP-1 / Glucagon (GCGR) — Triple Agonist |
| Half-Life (Research Models) | ~6 Days (C20 Fatty Diacid Albumin Binding) |
| Purity | ≥99% (HPLC Verified) |
| Identity Confirmation | LC-MS Verified Per Batch |
| Form | Lyophilized Powder |
| Solubility | Sterile Water or Bacteriostatic Water |
| Storage | −20°C, Protected from Light and Moisture |
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic 39-amino acid unimolecular triple-hormone receptor agonist and is supplied exclusively for laboratory and preclinical research applications. Identified by CAS Number 2381089-83-2, Retatrutide is widely referenced in metabolic and obesity research literature as the first characterized triple agonist targeting the GIP receptor, GLP-1 receptor, and glucagon receptor (GCGR) simultaneously within a single molecular scaffold.
The peptide backbone is derived from GIP and modified to introduce glucagon receptor activity. A C20 fatty diacid moiety facilitates albumin binding, protecting the peptide from enzymatic degradation and extending its half-life to approximately 6 days in research models — a structural feature that distinguishes it from shorter-acting GLP-1 analogs and supports weekly administration protocols in preclinical study designs.
Retatrutide is characterized in research literature for a tuned potency hierarchy: highest activity at GIP receptors for lipid buffering research, moderate activity at GLP-1 receptors for satiety pathway investigation, and carefully calibrated glucagon receptor activity for energy expenditure modeling — without the hyperglycemia associated with unbalanced glucagon stimulation in research models. This triple-receptor architecture enables researchers to study both energy intake suppression and active energy expenditure simultaneously, a mechanistic capability not available with dual or mono agonist research tools.
Manufactured under controlled conditions and supplied in lyophilized form, Retatrutide is commonly utilized by qualified researchers requiring high-purity, batch-consistent materials for controlled experimental studies.
This product is clearly labeled and distributed strictly as a Research Use Only (RUO) material and is not approved for human or veterinary use.
Experimental Research Applications
In scientific literature, Retatrutide has been investigated in a variety of experimental settings, including:
- Triple receptor agonism research — GIP, GLP-1, and glucagon pathway co-activation
- Obesity and body weight regulation mechanism studies
- Energy expenditure and thermogenesis pathway research (glucagon receptor)
- Visceral and hepatic fat reduction and MASLD/hepatic steatosis models
- Type 2 diabetes, insulin resistance, and glycemic control research
- Lipid buffering and GIP receptor signaling studies
- Satiety and appetite regulation pathway investigations
- Albumin binding, acylation chemistry, and extended half-life peptide research
- Comparative mono/dual/triple agonist mechanistic studies
These studies are conducted exclusively within laboratory and preclinical environments and are intended for mechanistic and observational research purposes.
Purity and Quality Control
Each batch of Retatrutide undergoes analytical testing to ensure:
✔ ≥99% purity verified by HPLC
✔ LC-MS molecular weight and sequence identity confirmed per batch
✔ Batch-to-batch consistency
✔ Professional documentation and traceability
✔ Controlled manufacturing standards
✔ Reliable performance for repeatable research applications
High analytical purity and strict quality control procedures help provide researchers with confidence in the consistency and reliability of each batch.
Key Research Features
- Triple-hormone receptor agonist — GIP + GLP-1 + Glucagon (GCGR)
- Tuned potency hierarchy across all three receptor targets
- C20 fatty diacid moiety — albumin binding, ~6-day half-life in research models
- Simultaneous energy intake and energy expenditure pathway modeling
- ≥99% HPLC-verified purity
- LC-MS sequence and molecular weight identity confirmed
- Lyophilized powder format
- Suitable for in vitro and preclinical research
- Batch-tested for consistency
- Research-grade manufacturing standards
- Professionally labeled and documented
Storage Recommendations
To maintain product stability and research integrity, Retatrutide should be:
- Stored at −20°C in a tightly sealed container
- Protected from light and moisture
- Reconstituted in sterile or bacteriostatic water
- Kept sealed until use
- Handled according to standard laboratory procedures
- Not subjected to repeated freeze-thaw cycles
Toxicology and Regulatory Information
- Currently an Investigational New Drug (IND) under active Phase 3 clinical investigation (TRIUMPH and TRANSCEND trial series)
- Not FDA-approved for any therapeutic indication as of current date
- Prohibited by the World Anti-Doping Agency (WADA) under S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics
- Supplied strictly as a Research Use Only (RUO) material
Why Choose Summit Pep Labs?
At Summit Pep Labs, we are committed to supplying researchers with premium-quality compounds manufactured to rigorous analytical standards.
Why Researchers Choose Summit Pep Labs
- ≥99% HPLC-verified purity
- LC-MS sequence and molecular weight identity confirmed per batch
- C20 acyl side chain integrity verified — critical for half-life dependent study designs
- Batch consistency and traceability
- Professional labeling and packaging
- Research-grade manufacturing standards
- Secure cold-chain shipping and quality assurance
- Commitment to reproducibility and reliability
Frequently Asked Questions
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic 39-amino acid triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, commonly referenced in scientific literature for metabolic research, obesity mechanism studies, hepatic steatosis models, and energy expenditure pathway investigations in laboratory and preclinical environments.
What distinguishes Retatrutide from dual agonists like tirzepatide?
Retatrutide adds glucagon receptor (GCGR) agonism to the GIP and GLP-1 receptor activity present in dual agonists. Glucagon receptor activation drives energy expenditure and thermogenesis, allowing researchers to study both energy intake suppression and active caloric expenditure simultaneously — a mechanistic capability not available with GIP/GLP-1 dual agonists or GLP-1 mono agonists.
Does glucagon receptor activity cause hyperglycemia in research models?
Research literature characterizes Retatrutide with a tuned potency ratio where the insulinotropic effects of GIP and GLP-1 receptor co-activation counterbalance the glucagon component. Clinical trial data reports improved glycemic control despite glucagon activation, making it a practical tool for studying glucagon-mediated energy expenditure independently of hyperglycemic confounds.
What is the significance of the C20 fatty diacid moiety?
The C20 fatty diacid side chain facilitates albumin binding, protecting the peptide from enzymatic degradation and extending half-life to approximately 6 days in research models. This structural feature supports weekly administration protocols in preclinical study designs and is verified per batch in our COA documentation.
Is Retatrutide approved for human use?
No. Retatrutide is currently an Investigational New Drug (IND) under Phase 3 clinical investigation and has not received FDA approval for any therapeutic indication. It is supplied exclusively as a Research Use Only (RUO) material.
What purity does Summit Pep Labs provide?
Each batch of Retatrutide is tested and verified to contain ≥99% purity using HPLC analytical methods, with LC-MS identity confirmation and C20 acyl side chain integrity verification per batch.
How is Retatrutide supplied?
Retatrutide is supplied as a lyophilized powder and packaged according to professional research standards.
How should Retatrutide be stored?
Store at −20°C, protected from light and moisture. Reconstitute with sterile or bacteriostatic water. Avoid repeated freeze-thaw cycles.
References
- Jastreboff AM et al. Triple hormone receptor agonist retatrutide for obesity. N Engl J Med. 2023
- Lincoff AM et al. TRIUMPH-4 Phase 3 trial — Retatrutide and osteoarthritis outcomes. 2025
- NCT06354660 — TRANSCEND-T2D-1 Phase 3 clinical trial. ClinicalTrials.gov
- PubChem Compound Summary — Retatrutide (LY3437943). CID 2381089-83-2
- National Center for Biotechnology Information (NCBI)
- U.S. Food and Drug Administration (FDA) — Investigational New Drug Framework
- World Anti-Doping Agency (WADA) Prohibited List — S2
Research Use Only Disclaimer
For Research Use Only (RUO).
This product is intended strictly for laboratory and scientific research purposes. It is not intended for human consumption, veterinary use, cosmetic applications, therapeutic use, or diagnostic purposes.
By purchasing this product, customers acknowledge that they are qualified researchers and agree to use these materials in accordance with all applicable laws and regulations.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Matt P. –
Shipping was fast, ordering was easy, customer service was great and responded quickly.
Josh Owens (verified owner) –
Great product, works well
Charles McCallum –
Retatrutide as described